Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 1.2 - Chapter

  • from 1 - Inflammatory Conditions
  • Edited by Derya Uluduz, Istanbul Üniversitesi
  • Anita Arsovska
  • Book:
    Rare Causes of Stroke
    Published online:
    06 October 2022
    Print publication:
    01 September 2022, pp 50-53

  • Summary

    Vogt Koyanagi Harada (VKH) disease is an idiopathic autoimmune disease primarily manifesting as bilateral, chronic, and diffuse granulomatous panuveitis associated with auditory, neurological, and integumentary findings. Clinical suspicious of VKH is female dominance, flu-like symptoms with meningismus preceding acute blurring of vision, ocular disease, recurrent aseptic meningitis with or without focal neurologic findings, sunset glow fundus. Patients has four clinical stages; prodromal or early stage, uveitic stage, convalescent stage which is characterized by depigmentation of the choroid, hair and skin, and chronic stage usually occurs in the first six months. The emergency or primary care physician may be the point of first contact with a patient with VKH disease. The key components of managing this disease are awareness of symptoms that lead to early diagnosis and a multidisciplinary approach. For patients with severe visual loss and bilateral serous retinal detachments, systemic prednisolone at 1-2mg/kg/day is started